~~<i id='05F1276B0B'><strike id='05F1276B0B'><tt id='05F1276B0B'><pre id='05F1276B0B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：hotspot 2025-10-01 12:35:56 - browse：77426

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The health care issue Democrats can’t solve: hospital reform

knowledge

focus

Wikipedia

entertainment

focus

Asidefromthestethoscope,thearound20-personGliateammanufacturestourniquets,earotoscopes,andcapstostop

WSS

Pregnancy discrimination could be enabled by AI

Bill would allow buprenorphine prescription for addiction via telehealth

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Why sickle cell disease is getting the first CRISPR treatment

All of Us, NIH's precision medicine initiative, gets a big boost

FDA needs staff influx to meet gene therapy needs, Marks says

hotspot

focus

knowledge

Psychedelics group wrestles with new pharma identity

What is microchimerism and how does it affect maternal health?

How one medical school became remarkably diverse

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Guidelines to prevent youth baseball injuries need more muscle

SCOTUS to consider access to abortion pill mifepristone

How one medical school became remarkably diverse

Pharma patents targeted by Biden in move to slash drug prices

Cancer drug shortages should be causing more outrage

Prime Medicine says its gene editing passes test in monkeys

focus

Americans' trust in science, scientist continues decline: Report

Radiology is caught between AI's potential and concern for patients

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Infant mortality in U.S. rose last year for first time in decades: CDC

Kidney transplant patients stopped immunosuppressants in trial

Key Senate panel to consider PBM, drug pricing reform package

Wikipedia

Wikipedia

entertainment

focus